17.05.2017 18:12:00
|
EQUITY ALERT: Rosen Law Firm Continues to Investigate Securities Claims Against Sinovac Biotech Ltd. - SVA
NEW YORK, May 17, 2017 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it is continuing to investigate potential securities claims on behalf of shareholders of Sinovac Biotech Ltd. (NASDAQ: SVA) resulting from allegations that Sinovac may have issued materially misleading business information to the investing public.
On December 21, 2016, an article published on SeekingAlpha.com revealed that recently disclosed court documents show that Sinovac Chairman and CEO Weidong Ying paid bribes to the Deputy Director General of the Center for Drug Evaluation for the China Food and Drug Administration and his wife in order to help advance drug applications and evaluations. On May 16, 2017, Sinovac disclosed that the SEC staff is conducting an enforcement inquiry related to the matters discussed in the article.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Sinovac investors. If you purchased shares of Sinovac, please visit the firm's website at http://www.rosenlegal.com/cases-1015.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked # 2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
kchan@rosenlegal.com
www.rosenlegal.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/equity-alert-rosen-law-firm-continues-to-investigate-securities-claims-against-sinovac-biotech-ltd---sva-300459345.html
SOURCE Rosen Law Firm, P.A.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Sinovac Biotech LtdShsmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Sinovac Biotech LtdShsmehr Analysen
Aktien in diesem Artikel
Sinovac Biotech LtdShs | 6,47 | -0,31% |
|